Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
0 hedge funds and large institutions have $0 invested in Mirati Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $2.52K → $0 (-$2.52K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
S
Sachetta
Lynnfield,
Massachusetts
|
-$1.41K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$1.11K |
MRTX Hedge Fund Activity: Q2 2024 in Review
0 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2024, worth a combined $0 — down 100% from $2.52K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of MRTX and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Sachetta, exiting entirely with an estimated $1.41K sold.
- 0 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2024, down from 2 in Q1 2024.
- Funds reported $0 of Mirati Therapeutics, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2024 and 2 closed out, a net change of -2 holders.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2024 was Sachetta, an estimated $1.41K sold.
Based on aggregated 13F filings for Q2 2024.